Pancreatic Cancer Research

ResearcherNankai UniversityActive in the last 2 years

Jing Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4289-4829; OpenAlex author ID A5100336933. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. Self-targeted liposomes for enhancing chemotherapeutic efficacy of pancreatic cancer by degrading the extracellular matrix and eradicating intra-tumoral bacter… Co-author DOI 10.1039/d5bm00786k↗
  2. Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B. Co-author DOI 10.1007/s00432-020-03384-7↗
  3. Dimethylaminomicheliolide (DMAMCL) Inhibits Cell Proliferation and Increases Apoptosis and Efficacy of Gemcitabine via Annexin A2 in Pancreatic Adenocarcinoma Last author DOI 10.21203/rs.3.rs-737712/v1↗
  4. Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway. Co-author DOI 10.18632/oncotarget.12391↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Siyu Zhang · 1 shared paper, 2025 · strength 0.25
  2. Linqi Shi · 1 shared paper, 2025 · strength 0.25
  3. Lei Yang · 2 shared papers, 2016–2021 · strength 0.17
  4. Yinan Yang · 2 shared papers, 2016–2021 · strength 0.17
  5. Mengmeng Zhu · 2 shared papers, 2016–2021 · strength 0.17
  6. Zhi Qi · 2 shared papers, 2016–2021 · strength 0.17
  7. Wencong Tian · 1 shared paper, 2021 · strength 0.12
  8. Jie Liu · 1 shared paper, 2021 · strength 0.12
  9. Lianyong Li · 1 shared paper, 2021 · strength 0.11
  10. Yanling Liu · 1 shared paper, 2021 · strength 0.11
  11. Kaihui Liu · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.